Intermediate‐risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long‐term outcome study

Abstract

Intermediate-risk surgically ablated patients do not need adjuvant RAI therapy and patients who failed to achieve ablation with first dose of (131) I may be dynamically risk stratified as high-risk category and managed aggressively.